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Association studies in candidate genes have been widely used to search for common low penetrance susceptibility
alleles, but few definite associations have been established. We have conducted association studies in breast cancer
using an empirical single nucleotide polymorphism (SNP) tagging approach to capture common genetic variation in
genes that are candidates for breast cancer based on their known function. We genotyped 710 SNPs in 120 candidate
genes in up to 4,400 breast cancer cases and 4,400 controls using a staged design. Correction for population
stratification was done using the genomic control method, on the basis of data from 280 genomic control SNPs.
Evidence for association with each SNP was assessed using a Cochran–Armitage trend test (p-trend) and a two-degrees
of freedom v
2 test for heterogeneity (p-het). The most significant single SNP (p-trend¼8310
 5) was not significant at
a nominal 5% level after adjusting for population stratification and multiple testing. To evaluate the overall evidence
for an excess of positive associations over the proportion expected by chance, we applied two global tests: the
admixture maximum likelihood (AML) test and the rank truncated product (RTP) test corrected for population
stratification. The admixture maximum likelihood experiment-wise test for association was significant for both the
heterogeneity test (p¼0.0031) and the trend test (p¼0.017), but no association was observed using the rank truncated
product method for either the heterogeneity test or the trend test (p ¼ 0.12 and p ¼ 0.24, respectively). Genes in the
cell-cycle control pathway and genes involved in steroid hormone metabolism and signalling were the main
contributors to the association. These results suggest that a proportion of SNPs in these candidate genes are
associated with breast cancer risk, but that the effects of individual SNPs is likely to be small. Large sample sizes from
multicentre collaboration will be needed to identify associated SNPs with certainty.
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Introduction
Breast cancer tends to cluster in families, with disease
being approximately 2-fold more common in ﬁrst-degree
relatives of cases [1]. The higher rate of most cancers in the
monozygotic twins of cases than in dizygotic twins or siblings
suggests that most of the familial clustering is the result of
inherited genetic variation rather than lifestyle or environ-
mental factors [2]. Some of this clustering occurs as part of
speciﬁc familial breast cancer syndromes where disease
results from single alleles conferring a high risk. However,
such alleles are rare in the population, and highly penetrant
variants of BRCA1 and BRCA2 account for less than 20% of
the genetic risk of breast cancer with other rarer high
penetrance genes such as TP53, ATM, and PTEN counting for
less than 5% [3]. Despite extensive efforts, linkage studies
have failed to map further more BRCA-like highly penetrant
cancer susceptibility genes [4]. Together with data on
patterns of familial occurrence of cancer that exclude cases
because of known high-risk genes, this argues strongly that
most genetic susceptibility results from the combined effects
of many genetic variants, each of which have a modest effect
individually [5]. Family-based linkage studies have been the
foundation for the many successes in mapping of genes
associated with Mendelian disorders, but they lack power to
detect alleles conferring moderate risks that are likely to be
the norm in complex disease. The main alternative to linkage
studies for disease gene mapping is the association study, in
which the frequency of a genetic variant in diseased
individuals (cases) and individuals without the disease
(controls) are compared [6,7]. Association studies for disease
genes are generally based on the ‘‘common variant: common
disease’’ hypothesis [8]. Allelic association is present when the
distribution of genotypes differs in cases and controls. Such
an association provides evidence that the locus under study,
or a neighbouring locus, is related to disease susceptibility.
Considerable research effort has been put into the search
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alleles over the past ten years. Most early association studies
were based on testing candidate functional polymorphisms in
candidate genes, but recently more emphasis has been placed
on an empirical approach in which a minimal set of ‘‘tagging’’
single nucleotide polymorphisms (SNPs) that efﬁciently
captures all the common genetic variation in a gene is
assayed [9]. In addition, high throughput genotyping tech-
nologies have made it possible to assess multiple candidate
genes. The analysis of such studies inevitably involves a large
number of statistical tests, and there has been much debate
about how to analyse the totality of such data, and, in
particular, how (or indeed whether) to carry out a correction
for multiple hypothesis testing. Most approaches to this
problem have considered this as a hypothesis-testing prob-
lem, in which the aim is to control the overall ‘‘experiment-
wise’’ type I error. Thus, the null hypothesis is that there is no
association between the disease and any SNPs in the set, and
the aim is to test whether this global null hypothesis of no
association can be rejected. A variety of methods has been
proposed to test the global null hypothesis [10–18]. Recently
we developed a novel method, the admixture maximum
likelihood (AML) test, which estimates both the proportion of
associated SNPs and their typical effect size [19]. We
compared the power of the AML method with several
previously proposed approaches by simulation and found
that the maximum likelihood approach performed similarly
to or better than all other tests across a wide range of
scenarios for the alternative hypothesis. The rank truncated
product (RTP) method also had good power, though some-
what inferior to the maximum likelihood approach in most
cases. A simple Bonferroni correction performed best only
when the number of associated SNPs was small.
We have been carrying out association studies in breast
cancer for over a decade, and over the past ﬁve years most of
our work has focussed on a comprehensive tagging approach
in candidate genes using a two-stage study design. We now
have data from up to 4,400 cases and 4,400 controls on 710
common variants in 117 candidate genes. Here we evaluate
the evidence for associations between this set of SNPs and
breast cancer using the AML and RTP methods
Results
Data were available for 710 SNPs in 120 genes. Genotype
frequencies for cases and controls are shown in Table S3.
Based on the trend test for association, 53 SNPs (7.5%) were
signiﬁcant at the 5% level, 17 (2.4%) at the 1% level, and one
(0.15%) at the 0.1% level. Only one SNP, in the estrogen
receptor a gene (trend test v
2¼15.6, p¼8310
 5) reaches the
p , 0.0001 level, which has been suggested an appropriate
threshold for candidate gene studies [9]. However, it failed to
reach this threshold after adjusting for population stratiﬁca-
tion by genomic control (p-trend adjusted¼0.00023). Nor was
it signiﬁcant at the 5% level after adjustment for multiple
testing using a permutation test that allows for correlation
between SNPs tested (the equivalent of a Bonferroni
correction for independent hypotheses). Figure 1 shows the
Q–Q plots for the univariate trend test using only the ﬁrst
case-control set. The Q–Q plot based on the test statistics
adjusted for genomic control follows the line of equivalence
for the ﬁrst 600 SNPs and then starts to deviate as would be
expected if a modest proportion of SNPs were associated with
disease.
The AML experiment-wise test for association was signiﬁ-
cant for both the heterogeneity test (p¼0.0031) and the trend
test (p¼0.017), but no association was observed using the RTP
method for either the heterogeneity test or the trend test (p¼
0.12 and p ¼ 0.24; respectively). Table 1 shows the results of
the AML experiment-wise tests for the complete set of SNPs
and for sets of SNPs categorised according to gene functional
group. The test for overall association was signiﬁcant for
SNPs in the cell-cycle control genes (p-heterogeneity ¼ 0.019,
p-trend ¼ 0.035), steroid hormone signalling and metabolism
genes (p-heterogeneity ¼ 0.010, p-trend ¼ 0.0080), and the
heterogeneous set of genes categorised as ‘‘other’’ (p-hetero-
geneity ¼ 0.0068, p-trend ¼ 0.12).
We reanalysed the data after excluding the most signiﬁcant
SNP (ESR1 rs3020314) and two SNPs (CASP8 rs1045485 and
TGFB1 rs1982073), which have been conﬁrmed as being
associated with breast cancer in pooled data from up to 20
studies in the Breast Cancer Association Consortium [20].
After excluding these SNPs the test for both heterogeneity
and trend remained signiﬁcant (p ¼ 0.0046 and p ¼ 0.031,
respectively). We also reanalysed the data after removing all
80 tSNPs in these genes. Only the heterogeneity test remained
signiﬁcant (p ¼ 0.015, p-trend ¼ 0.12). The test for the steroid
hormone metabolism pathway remained signiﬁcant after
removing the most signiﬁcant single SNP (p-heterogeneity ¼
0.018, p-trend ¼0.012) and all SNPs in ESR1 (p-heterogeneity
¼ 0.10, p-trend ¼ 0.044). The signiﬁcance of the tests for
association of ‘‘other’’ genes became borderline after remov-
ing the most single signiﬁcant SNP in CASP8 (p-heterogeneity
¼0.0065, p-trend¼0.13) and after removing all three SNPs in
CASP8 (p-heterogeneity ¼ 0.0058, p-trend ¼ 0.12).
Data from the genomic control SNPs indicate some
evidence of inﬂation of the test statistics. Given that k, the
measure of bias due to population stratiﬁcation, is estimated
with error, we repeated the AML tests assuming more
extreme levels of bias. We used the estimate of the variance
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Author Summary
The polygenic model of cancer susceptibility suggests that multiple
alleles contribute to the excess familial risk of most common
cancers. Candidate gene association studies have been a commonly
used approach in the search for such alleles. We have investigated
over 700 common variants in genes that are candidates for breast
cancer susceptibility in a large case-control study of breast cancer,
but no single variant was identified at an appropriate level of
statistical significance. The purpose of this study was to consider
these data as a whole, using a novel method, the admixture
maximum likelihood test, to test the hypothesis that a proportion
(unknown) of the variants we investigated are associated with breast
cancer. After adjusting for population substructure, we found
evidence for association that was robust to all but the most
extreme assumptions about the degree of population stratification.
Genes in the cell-cycle control and steroid hormone metabolism and
signalling pathways were the main contributors. These results
suggest that a proportion of single nucleotide polymorphisms
(SNPs) in these candidate genes are associated with breast cancer
risk, but that the effects of individual SNPs are likely to be small.
Large sample sizes from multicentre collaboration will be needed to
identify associated SNPs with certainty.(r
2) and the inﬂation parameter (k) to carry out sensitivity
analyses with the inﬂation parameter set at kþr and kþ2r.
The test for heterogeneity remained signiﬁcant for an
inﬂation factors of k þ r (p ¼ 0.012), but not for the most
extreme estimate of the bias (inﬂation parameter¼kþ2r, p¼
0.060). The AML trend test was not signiﬁcant under either
scenario (p¼0.070 and p¼0.20, respectively). Other methods
to deal with population stratiﬁcation have been suggested,
each of which has some advantages and disadvantages. The
method of structured association uses the genomic control
SNPs to assign individuals to speciﬁc subpopulations, which
can then be used in stratiﬁed analyses. This method works
well for a small number of discrete of subpopulations but less
well for more complex population structures [21]. Gorroo-
churn and colleagues suggested that the v
2
test statistics come
from a noncentral v
2 distribution, and that the noncentrality
parameter can be estimated directly using the genomic
control SNPs [22]. We adapted this method and estimated
the noncentrality parameter (g) by maximum likelihood. The
AML tests for association obtained using this method were
similar to those used in the genomic control method (data not
shown).
It is possible that our results are biased because of
systematic differences in genotype frequencies between the
incident and prevalent cases (survival bias). We therefore
carried out a case only analysis to compare genotype
frequencies in incident and prevalent cases. There was no
evidence of association using the AML test (p ¼ 0.36).
Discussion
In the past ﬁve years we have evaluated over 700 common
genetic variants in 120 genes that are candidates for breast
cancer susceptibility in a case-control study of over 4,400
cases and 4,400 controls. Based on univariate analyses no
deﬁnite susceptibility alleles have emerged from this research
effort. Only one SNP signiﬁcant at p , 0.0001 was identiﬁed
in this dataset, and this became less signiﬁcant after adjusting
for population stratiﬁcation. This association was not
signiﬁcant at a nominal p , 0.05 after adjusting for multiple
testing. However, it is not clear that this is an appropriate
adjustment in such studies, because the result is then highly
dependent on the number of SNPs that happen to have been
typed at a given time.
The lack of evidence of association in these SNPs may
indicate that these genes we have studied do not harbour any
susceptibility variants. An alternative explanation is that one
or more of the SNPs is associated with disease, but we do not
have sufﬁcient statistical power to detect these with appro-
priate highly stringent levels of statistical signiﬁcance. For
individual variants, the statistical power of the study depends
on the at-risk allele frequency, the risks conferred, and the
genetic model. For example, assuming that the causative SNP
is tagged with r
2 ¼ 0.8, a type I error rate of 10
 5, and
genotyping success rate of 0.95, the staged study has 67%
power to detect a dominant allele with a minor allele
frequency (MAF) of 0.05 with an odds ratio of 1.5 or 69%
power to detect a dominant allele with MAF of 0.25 with an
odds ratio of 1.3. Power to detect recessive alleles is less 39%
for an allele with MAF of 0.25 and an odds ratio of 1.5 and
46% for an allele with MAF 0.5 and an odds ratio of 1.3.
We have recently shown that methods that take into
account the totality of the data have greater power to detect
association than simple methods, such as the Bonferroni
correction (or an equivalent such as permutation testing that
Figure 1. Q–Q Plot for Association of 710 SNPs in Candidate Genes with Breast Cancer Based on First Stage Data
doi:10.1371/journal.pgen.0030042.g001
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Candidate Genes and Breast Cancer Risktakes into account correlation of the SNPs), where there are
multiple SNPs associated with disease [19]. We therefore
tested the hypothesis that subsets of the SNPs we have
assessed are associated with breast cancer. Using the AML
method, we found evidence for an overall association
between common genetic variation in 120 candidate genes
and breast cancer. In particular, we found some evidence of
an association with SNPs in genes involved in cell-cycle
control and steroid hormone metabolism. We also found
evidence for population stratiﬁcation in our study using data
from 280 genomic control SNPs and corrected for this in all
the analyses. However, the estimate of the inﬂation factor
based on 280 SNPs is imprecise. We therefore carried out a
sensitivity analysis using more extreme values of the inﬂation
factor based on its variance. Under all but the most extreme
assumptions (i.e., the upper 95% conﬁdence limit of the
inﬂation factor estimate) the global test of association
remained signiﬁcant. We therefore conclude that some
proportion of the variants we have investigated are likely to
be associated with breast cancer. In support of this
conclusion, it is notable that stronger evidence of association
has emerged for two of the SNPs we analysed, through
collaborative analyses by the Breast Cancer Association
Consortium [23]. One of these, in CASP8, was originally
identiﬁed in another study but also showed evidence in our
study [24]. The other, in TGFB1, was originally identiﬁed in a
subset of cases and controls from our study [25].
Thus, our data provide further evidence for the existence
of common low penetrance variants. The most efﬁcient way
to identify such variants is not clear, and considerable
research funding and effort is currently being focussed on
an empirical genome-wide approach rather than the candi-
date gene approach that has generally been the norm. The
relative merits of the two approaches have not yet been
deﬁned, but our data suggest that the candidate gene
approach may still be useful. However, our results also
highlight the fact that alleles with modest effects, i.e., those
conferring relative risks of .1.5, are likely to be the
exception, and multicentre collaborations will be needed to
generate adequate sample sizes.
Materials and Methods
Study participants. Patients were drawn from Studies of Epidemi-
ology and Risk factors in Cancer Heredity (SEARCH), an ongoing
population-based study, with individuals ascertained through the East
Anglian Cancer Registry. All patients diagnosed with invasive breast
cancer below age 55 years since 1991 and still alive in 1996 (prevalent
cases, median age 48 years), together with all those diagnosed below
age 70 years between 1996 and the present (incident cases, median
age 54 years) are eligible to take part. As of 1 August 2005 there have
been 12,767 eligible patients. Of these, 2,284 were not contacted
because their general practitioner did not respond or thought that it
would be inappropriate to contact the patient. Of the 10,583 patients
who were contacted, 67% have returned a questionnaire, and 64%
provided a blood sample for DNA analysis. Eligible patients who did
not take part in the study were similar to participants except, as
might be expected, the proportion of clinical stage III/IV cases was
somewhat higher in nonparticipants (10% versus 5%). Female
controls were randomly selected from the Norfolk component of
the European Prospective Investigation of Cancer (EPIC). EPIC is a
prospective study of diet and cancer being carried out in nine
European countries. The EPIC–Norfolk cohort comprises 25,000
individuals resident in Norfolk, East Anglia—the same region from
which the cases have been recruited. Controls are not matched to
cases, but are broadly similar in age (42–81 years). The ethnic
background of both cases and controls as reported on the
questionnaires is similar, with .98% being white. The study is
approved by the Eastern Region Multicentre Research Ethics
Committee, and all patients gave written informed consent.
The total number of cases used in genetic analyses was 4,473, of
whom 27% are prevalent cases. The samples were split into two sets
in order to save DNA and reduced genotyping costs: the ﬁrst set (n¼
2,270 cases and 2,280 controls) was genotyped for all SNPs, and the
second set (n ¼ 2,203 cases and 2,280 controls) were then tested for
those SNPs that showed marginally signiﬁcant associations in set 1 (p-
heterogeneity or p-trend , 0.1). Two SNPs were genotyped in stage 2
as a result of a multimarker haplotype association (see below). This
staged approach substantially reduces genotyping costs without
signiﬁcantly affecting statistical power. Cases were randomly selected
for set 1 from the ﬁrst 3,500 recruited, with set 2 comprising the
remainder of these plus the next 974 incident cases recruited. As the
prevalent cases were recruited ﬁrst, the proportion of prevalent cases
was somewhat higher in set 1 than set 2 (33% versus 20%). Median
age at diagnosis is similar in both sets (51 and 52 years old,
respectively). There was no signiﬁcant difference in the morphology,
histopathological grade, or clinical stage of the cases by set or by
prevalent/incident status.
Candidate gene and SNP selection. We selected genes that encode
proteins in cellular pathways that are likely to be involved in breast
carcinogenesis. The major pathways we studied were steroid hormone
metabolism and signalling, double strand break DNA repair,
oxidative damage repair, epigenetic modiﬁers, and cell-cycle control.
We also tested genes in the 17q21 region commonly ampliﬁed in








a p-Value of Most
Significant SNP
b
AML Heterogeneity AML Trend
17q21 Amplicon 10 24 [29] .013 .67 .45
Animal models 13 34 [30] .0023 .097 .11
Cell-cycle control 18 112 [31] .0048 .019 .035
DNA repair 20 164 [32–35] .027 .92 .96
Epigenetic modifiers 13 67 [36] .0044 .26 .21
Growth factors 8 43 [25,37] .019 .085 .13
Oxidative damage repair 11 65 [38] .046 .42 .95
Steroid hormone
metabolism and signalling
8 104 [39] .00023 .010 .0080
Others 19 97 [24] .012 .0068 .12
Total 120 710 .0031 .017
aCited papers do not necessarily report totality of data for each pathway as some unpublished data.
bBased on trend test adjusted for genomic control.
doi:10.1371/journal.pgen.0030042.t001
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Candidate Genes and Breast Cancer Riskbreast tumours, several genes that have been found to be important
in a variety of animal models of cancer, and some carcinogen
metabolism genes. For some pathways, only a small subset of genes
was selected for study. For the purpose of subgroup analysis, SNPs in
these genes were categorised as ‘‘other’’ together with the SNPs in
carcinogen metabolism genes. The genes and the number of SNPs
assayed for each are shown in Table S1. The principal hypothesis
underlying our approach is that there are one or more common SNPs
in the genes of interest that are associated with an altered risk of
breast cancer. We therefore aimed to identify a set of tagging SNPs
(tSNPs) that efﬁciently tags all the known common variants (MAF .
0.05) and is likely to tag most of the unknown common variants. We
used data from the International HapMap project (http://www.
hapmap.org) or resequencing data from the National Institute of
Environmental Health Sciences Environmental Genome Project
(EGP) (http://www.niehs.nih.gov/envgenom/home.htm). The details of
the methodology for tag SNP selection varied over time, but broadly
speaking we have aimed to deﬁne a set of tagging SNPs such that all
known common variants are correlated with a tSNP with r
2 of .0.8.
Some SNPs are poorly correlated with other single SNPs but may be
efﬁciently tagged by a haplotype deﬁned by multiple SNPs, thus
reducing the number of tagging SNPs needed [26]. As an alternative,
therefore, we aimed for the correlation between each SNP and a
haplotype of tagging SNPs to be at .0.8. For some genes, little
information on the occurrence of common variants was available at
the time the gene was studied, and the SNPs were selected for analysis
based on predicted functional effects; Table S1 indicates which genes
have been comprehensively tagged. We also obtained genotype data
for our cases and controls for 280 randomly selected, unlinked SNPs,
which were genotyped as part of an ongoing genome-wide association
study (see Table S2). Data on these SNPs were used to adjust for
population stratiﬁcation using the genomic control method.
Genotyping methods. We genotyped all samples using the ABI
PRISM 7900 sequence detection system or ‘‘Taqman’’ (Applied
Biosystems, http://www.appliedbiosystems.com). Genomic DNA for
set 1 samples was whole genome ampliﬁed by primer extension
preampliﬁcation (PEP, protocol available on request). Genotype
calling between PEP-ampliﬁed DNA and native genomic DNA was
compared for eight Taqman assays, and the concordance was 100%.
We carried out PCR on 10 ng of whole-genome ampliﬁed genomic
DNA for set 1 and native genomic DNA for set 2 using TaqMan
universal PCR master mix (Applied Biosystems), forward and reverse
primers, and FAM- and VIC- labelled probes designed by Applied
Biosystems (ABI Assay-by-Designs) in a 5-ll reaction. We read the
completed PCRs on an ABI PRISM 7900 Sequence Detector in end-
point mode using the Allelic Discrimination Sequence Detector
software (Applied Biosystems). Cases and controls were arrayed
together in 12 384-well plates, and a 13th plate contained eight
duplicate samples from each of the 12 plates to ensure a good quality
of genotyping. Each 384-well plate included two nontemplate
controls. Concordance for duplicate samples was .98% for all
assays. Failed genotypes were not repeated (the rate for failed
genotypes did not exceed 8.3% for any of the SNPs under study).
Genomic control SNPs were genotyped by Perlegen Sciences (http://
www.perlegen.com) using an oligonucleotide array methodology.
Statistical methods. Association between disease and genotype for
each SNP was assessed using two tests, the one-degree of freedom
Cochran–Armitage trend test and the general two-degrees of
freedom v
2 test (heterogeneity test). Results for all tests were
summarised in Q–Q plots, in which the ordered test statistics are
plotted against the expected statistic given the rank.
To assess the overall evidence for an excess of associations, we
applied two approaches, the AML and RTP methods, which are
described in detail elsewhere [17,19]. In brief, the AML method
formulates the alternative hypothesis in terms of the probability that
a given SNP is associated with disease (a) and a measure effect size.
When a SNP is associated with disease, the calculated v
2 statistic will
be distributed, asymptotically, as a noncentral v
2 distribution with
the usual degrees of freedom and a noncentrality parameter g. The
noncentrality parameter is a measure of the size of effect of the SNP,
is dependent on sample size, and is closely related to the contribution
of the SNP to the genetic variance of the trait. If g is assumed to be
the same for each associated SNP, then both a and g can be estimated
by maximum likelihood, and a test of the null hypothesis can then be
derived as a likelihood ratio test. Where (as is the case here) some
SNPs are correlated, the full likelihood is no longer straightforward,
but pseudo-maximum likelihood estimates can still be generated by
the same procedure, as if the SNPs were independent. Statistical
signiﬁcance can then be determined by simulation. The AML method
was applied to both the trend and heterogeneity tests. The RTP is
simply the product of the K (arbitrary) most signiﬁcant p-values from
L hypothesis tests [17]. A limitation of the RTP is the need to select a
truncation point. While this may be straightforward in the context of
a genome-wide study where it reduces the exploratory hypotheses to
a deﬁned candidate set, it is rather arbitrary in the context of
candidate gene studies. For the purpose of these analyses we chose K
¼ 5. We adjusted all analyses for cryptic population stratiﬁcation
using the method described by Devlin and Roeder [27]. An inﬂation
factor (k) was estimated from the mean of the X
2
trend statistics
generated on 280 unlinked, randomly selected SNPs typed on a subset
of 4,037 cases and 4,012 controls as part of a separate genome-wide
association study. A list of these SNPs is provided in the
supplementary material. The average call rate was 99.0% in cases
and 98.9% in controls. The inﬂation of the test statistic, adjusted for
sample size, was estimated to be 1.15 (95% CI 0.94–1.36) for the trend
test and 1.05 (95% CI 0.92–1.19) for the heterogeneity test.
Association tests for individual SNPs will not be independent if the
markers are in linkage disequilibrium, and the application of both
methods needs to allow for the correlation structure of the data.
Simulations, based on permuting case-control status whilst retaining
the correlation structure among makers, provide a robust approach
for obtaining signiﬁcance levels for these global tests. However,
permutation testing is complicated by the use of a staged study design
where only those SNPs signiﬁcant in the ﬁrst stage data are genotyped
for the complete set of cases and controls. We allowed for this using
the method proposed by Dudbridge [28] in which a subset of the ﬁrst
stage date is used as the simulated ﬁrst stage data, selecting markers
on the basis of that subset, and using the remainder of the ﬁrst stage
as the simulated second stage.
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